News
-
Personalising Treatment for Europe’s most common Leukaemia – new Sucess Story published
Chronic lymphocytic leukaemia (CLL) is the most common form of leukaemia in Europe, and despite significant medical advances, it remains incurable. The CLL-CLUE project utilised Functional Precision Medicine (FPM) to improve the treatment outcome of CLL. The consortium used a specific targeted drug (a PI3K inhibitor) as a model to understand how these therapies change the internal communication…
-
White Paper on Advancing Precision Oncology Treatment and Testing across Europe
The European Federation of Pharmaceutical Industries and Associations (EFPIA) has published the white paper “Advancing precision oncology treatment and testing across Europe: An evidence-based roadmap for healthcare system stakeholders to improve cancer care”.
-
Video Interview with Ejnar Moltzen
At the joint ICPerMed and EP PerMed Conference in Prague, we had the opportunity to discuss with Ejnar Moltzen the origins of personalised medicine within the scope of genomic research around 20 years ago and how it has progressed from regional pilot projects to national implementations in recent years.
-
EMA Consultation on the Guideline Revision on Good Pharmacogenomic Practice
The European Medicines Agency (EMA) has opened an an online consultation on its concept paper on the revision of the guideline on good pharmacogenomic practice.
EP PerMed Fast Track 2026
The EP PerMed Fast Track Programme 2026 offers targeted support to accelerate the validation and adoption of innovative personalised medicine solutions. The programme helps early-stage innovations progress by at least one Technology Readiness Level through dedicated validation studies carried out together with specialised European validation centres.
Citizen Awareness of Personalised Medicine
Your opinion matters!
Have you been involved in a personalised treatment or are you aware of personalised medicine approaches?
EP PerMed likes to understand how well people are informed about personalised medicine, how they perceive it, and their thoughts on its potential benefits and challenges.
The anonymous survey contains 36 questions and takes approximately 10-15 minutes to complete. It is currently available in: English, Czech, Danish, Finnish, French, German, Greek, Italian, Norwegian, Dutch, Polish, Portuguese, Romanian, Spanish, Swedish and Turkish.
Mission & Objectives
EP PerMed Podcast ‘The Science of You’
The second season of the EP PerMed podcast tells four powerful stories of patients and former patients who have benefited from personalised medicine. With topics ranging from oncology and rare genetic disorders to preventive surgery and cardiovascular diseases, this season illustrates real human experiences, showing how tailored therapies are transforming the treatment process into a more effective and informed one.